Palbociclib induces activation of AMPK and inhibits hepatocellular carcinoma in a CDK4/6‐independent manner
Sign Up to like & getrecommendations! Published in 2017 at "Molecular Oncology"
DOI: 10.1002/1878-0261.12072
Abstract: Palbociclib, a CDK4/6 inhibitor, has recently been approved for hormone receptor‐positive breast cancer patients. The effects of palbociclib as a treatment for other malignancies, including hepatocellular carcinoma (HCC), are of great clinical interest and are… read more here.
Keywords: hepatocellular carcinoma; palbociclib; hcc; pp5 ampk ... See more keywords
Combination of cyclin-dependent kinase and immune checkpoint inhibitors for the treatment of bladder cancer
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Immunology, Immunotherapy"
DOI: 10.1007/s00262-020-02609-5
Abstract: Perturbation of the CDK4/6 pathway is frequently observed in advanced bladder cancer. We investigated the potential of targeting this pathway alone or in combination with chemotherapy or immunotherapy as a therapeutic approach for the treatment… read more here.
Keywords: bladder cancer; palbociclib; treatment; cancer ... See more keywords
A single institution experience with palbociclib toxicity requiring dose modifications
Sign Up to like & getrecommendations! Published in 2017 at "Breast Cancer Research and Treatment"
DOI: 10.1007/s10549-017-4606-9
Abstract: PurposeSince the widespread implementation of adding palbociclib to endocrine therapy in clinical practice, myelosuppression is becoming increasingly recognized as a toxicity that may lead to dose modification. We aimed to characterize toxicities observed with palbociclib… read more here.
Keywords: palbociclib; palbociclib dose; dose modification; toxicity ... See more keywords
Comparative efficacy of palbociclib, ribociclib and abemaciclib for ER+ metastatic breast cancer: an adjusted indirect analysis of randomized controlled trials
Sign Up to like & getrecommendations! Published in 2019 at "Breast Cancer Research and Treatment"
DOI: 10.1007/s10549-019-05133-y
Abstract: BackgroundSeveral trials have demonstrated the benefit of anti-CDK4/6 inhibitors plus endocrine therapy in estrogen receptor-positive (ER+) advanced breast cancer (BC), in first or subsequent lines of therapy. However, due to the lack of direct/indirect comparisons,… read more here.
Keywords: palbociclib; palbociclib ribociclib; ribociclib abemaciclib; analysis ... See more keywords
Impact of early dose intensity reduction of Palbociclib on clinical outcomes in patients with hormone-receptor-positive metastatic breast cancer
Sign Up to like & getrecommendations! Published in 2020 at "Breast Cancer Research and Treatment"
DOI: 10.1007/s10549-020-05793-1
Abstract: Palbociclib is commonly added to an aromatase inhibitor (AI) as first-line therapy in ER + HER2- metastatic breast cancer (MBC). There are no data on the effect of the relative dose intensity (RDI) of palbociclib in first-line… read more here.
Keywords: reduction; palbociclib; first line; breast cancer ... See more keywords
Real-world experience of palbociclib and ribociclib: novel oral therapy in metastatic breast cancer.
Sign Up to like & getrecommendations! Published in 2020 at "International Journal of Clinical Pharmacy"
DOI: 10.1007/s11096-020-01193-z
Abstract: Background Palbociclib and ribociclib are novel oral agents in hormone receptor-positive metastatic breast cancer. Neutropenia is a common adverse event associated with these treatments and its clinical management often requires regimen changes, such as cycle… read more here.
Keywords: regimen changes; palbociclib; metastatic breast; breast cancer ... See more keywords
CDK4/6 inhibitor palbociclib enhances the effect of pyrotinib in HER2-positive breast cancer.
Sign Up to like & getrecommendations! Published in 2019 at "Cancer letters"
DOI: 10.1016/j.canlet.2019.01.005
Abstract: Human epidermal growth factor receptor 2 (HER2) is amplified in about 20% breast cancers. Treat of HER2 positive breast cancers has been greatly promoted in last few years, but the accompany HER2 blockade has hindered… read more here.
Keywords: palbociclib; inhibitor; her2 positive; breast ... See more keywords
Real‐World Experience of Palbociclib‐Induced Adverse Events and Compliance With Complete Blood Count Monitoring in Women With Hormone Receptor–Positive/HER2‐Negative Metastatic Breast Cancer
Sign Up to like & getrecommendations! Published in 2019 at "Clinical Breast Cancer"
DOI: 10.1016/j.clbc.2018.09.002
Abstract: Micro‐Abstract Palbociclib therapy in hormone receptor–positive metastatic breast cancer patients may result in adverse events such as neutropenia, and stringent monitoring of complete blood count is advised. The current study found good compliance with guidelines… read more here.
Keywords: palbociclib; breast; compliance; breast cancer ... See more keywords
Discovery of a novel covalent CDK4/6 inhibitor based on palbociclib scaffold.
Sign Up to like & getrecommendations! Published in 2021 at "European journal of medicinal chemistry"
DOI: 10.1016/j.ejmech.2021.113432
Abstract: Cyclin-dependent kinases 4 and 6 (CDK4/6), which are involved in dynamic regulation of cell cycle, play an indispensable role in controlling the tumor growth. Here, based on the scaffold of palbociclib, we designed and synthesized… read more here.
Keywords: palbociclib; discovery novel; covalent cdk4; novel covalent ... See more keywords
Reproductive and Developmental Toxicity Assessment of Palbociclib, a CDK4/6 Inhibitor, in Sprague-Dawley Rats and New Zealand White Rabbits.
Sign Up to like & getrecommendations! Published in 2019 at "Reproductive toxicology"
DOI: 10.1016/j.reprotox.2019.07.016
Abstract: Palbociclib is a selective inhibitor of the cyclin-dependent kinase (CDK) 4/6, approved for the treatment of breast cancer. We assessed the potential effects of oral administration of palbociclib on reproduction and development. There were no… read more here.
Keywords: palbociclib; inhibitor; toxicity; developmental toxicity ... See more keywords
Use of Gastrointestinal Simulator, Mass Transport Analysis, and Absorption Simulation to Investigate the Impact of pH Modifiers in Mitigating Weakly Basic Drugs' Performance Issues Related to Gastric pH: Palbociclib Case Study.
Sign Up to like & getrecommendations! Published in 2022 at "Molecular pharmaceutics"
DOI: 10.1021/acs.molpharmaceut.2c00545
Abstract: It is well known that reduced gastric acidity, for example with concomitant administration of acid reducing agents, can result in variable pharmacokinetics and decreased absorption of weakly basic drugs. It is important to identify the… read more here.
Keywords: dissolution; palbociclib; modifiers mitigating; absorption ... See more keywords